Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 6,253,467 | $10,130,617 | 0.02% | |
| 2. | Sio Capital Michael Castor | 1,954,715 | $3,166,638 | -10% | 0.45% |
| 3. | DAFNA Capital Management Nathan Fischel | 1,567,561 | $2,539,449 | 0.58% | |
| 4. | Kynam Capital Derrick Tang | 1,566,317 | $2,537,434 | 0.16% | |
| 5. | Ikarian Capital Neil Shahrestani | 1,492,229 | $2,417,411 | 0.2% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.72 | 150,000 | $257,925.00 | 300,000 | 2026-07-17 | Filing | |
| $1.74 | 150,000 | $261,000.00 | 300,000 | 2026-07-09 | Filing | |
| $1.59 | 150,000 | $238,500.00 | 150,000 | 2026-07-07 | Filing | |
| $1.54 | 150,000 | $231,000.00 | 150,000 | 2026-06-26 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 150,000 | $279,000 | 0.02% | |
| 2. | 64,000 | $119,040 | 0% | |
| 3. | 25,000 | $46,500 | 0% | |
| 4. | 12,500 | $23,250 | 0% | |
| 5. | 10,500 | $19,530 | 0.01% |